AYALA PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.555 USD | +0.91% |
|
-2.97% | -16.79% |
Valuation
| Fiscal Period: December | 2023 |
|---|---|
| Capitalization 1 | 7.935 |
| Enterprise Value (EV) 1 | 11.37 |
| P/E ratio | -0.08 x |
| Yield | - |
| Capitalization / Revenue | 610 x |
| EV / Revenue | 875 x |
| EV / EBITDA | -0.33 x |
| EV / FCF | -3,503,334 x |
| FCF Yield | -0% |
| Price to Book | -0.32 x |
| Nbr of stocks (in thousands) | 11,897 |
| Reference price 2 | 0.6670 |
| Announcement Date | 4/16/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net sales 1 | 0.692 | 0.013 |
| EBITDA 1 | -37.34 | -34.9 |
| EBIT 1 | -37.5 | -35.27 |
| Operating Margin | -5,419.51% | -271,276.92% |
| Earnings before Tax (EBT) 1 | -37.43 | -51.98 |
| Net income 1 | -38.01 | -48.07 |
| Net margin | -5,493.21% | -369,784.62% |
| EPS 2 | -13.13 | -7.987 |
| Free Cash Flow | - | -3.245 |
| FCF margin | - | -24,963.46% |
| FCF Conversion (EBITDA) | - | - |
| FCF Conversion (Net income) | - | - |
| Dividend per Share | - | - |
| Announcement Date | 4/16/24 | 4/16/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 |
|---|---|---|
| Net Debt 1 | - | 3.43 |
| Net Cash position 1 | 0.66 | - |
| Leverage (Debt/EBITDA) | - | -0.0984 x |
| Free Cash Flow | - | -3.25 |
| ROE (net income / shareholders' equity) | - | 377% |
| ROA (Net income/ Total Assets) | - | -181% |
| Assets 1 | - | 26.55 |
| Book Value Per Share 2 | -0.3800 | -2.050 |
| Cash Flow per Share 2 | 0.8300 | 0.4100 |
| Capex | - | - |
| Capex / Sales | - | - |
| Announcement Date | 4/16/24 | 4/16/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.555
Average target price
-
Chiffre d''affaires - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.79% | 23.66M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ADXS Stock
- Financials Ayala Pharmaceuticals, Inc.
